ProShare Advisors
TRVI icon

ProShare Advisors’s Trevi Therapeutics TRVI Stock Holding History

ProShare Advisors’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$349K Sell
18,691
-905
-5% -$13.2K ﹤0.01% 1329
2026
Q1 		$234K Sell
19,596
-2,673
-12% -$29.9K ﹤0.01% 1478
2025
Q4 		$279K Buy
22,269
+2,947
+15% +$34.1K ﹤0.01% 1501
2025
Q3 		$177K Sell
19,322
-33
-0.2% -$247 ﹤0.01% 1722
2025
Q2 		$106K Sell
19,355
-805
-4% -$5.01K ﹤0.01% 1871
2025
Q1 		$127K Sell
20,160
-525
-3% -$2.5K ﹤0.01% 1786
2024
Q4 		$85.2K Buy
20,685
+9,589
+86% +$30.7K ﹤0.01% 2102
2024
Q3 		$37.1K Buy
+11,096
New +$33K ﹤0.01% 2010

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

ProShare Advisors's TRVI Position: Q2 2026 in Review

ProShare Advisors reduced its Trevi Therapeutics (TRVI) stake by 4.6% in Q2 2026, selling an estimated $13.2K and leaving 18,691 shares worth $349K. The position accounts for ﹤0.01% of the portfolio, ranked #1329.

ProShare Advisors first reported a position in TRVI in Q3 2024 and has held it in 8 quarters since. 218 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • ProShare Advisors held 18,691 shares of Trevi Therapeutics worth $349K as of Q2 2026.
  • ProShare Advisors sold 905 Trevi Therapeutics shares in Q2 2026, an estimated $13.2K.
  • Trevi Therapeutics made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #1329 holding.
  • ProShare Advisors first reported a position in Trevi Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • 218 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.